Global Health Innovative Technology Fund

Bradaverse Education Completes Name Change

Retrieved on: 
Wednesday, March 15, 2023

HONG KONG, Mar 15, 2023 - (ACN Newswire) - Bradaverse Education (Int'l) Investments Group Limited ("Bradaverse Education" or the "Company", together with its subsidiaries, collectively referred to as the "Group"; stock code: 1082) is the new name of formerly Hong Kong Education (Int'l) Investments Limited, effective from February this year.

Key Points: 
  • HONG KONG, Mar 15, 2023 - (ACN Newswire) - Bradaverse Education (Int'l) Investments Group Limited ("Bradaverse Education" or the "Company", together with its subsidiaries, collectively referred to as the "Group"; stock code: 1082) is the new name of formerly Hong Kong Education (Int'l) Investments Limited, effective from February this year.
  • The new name Bradaverse Education is reflective of the fresh corporate image of the Group, highlighting its aspiration to expand high-tech and innovative education services, as well as actively develop virtual reality ("VR") and digital entertainment business, and its metaverse-geared business positioning and strategy.
  • Therefore, the Group, through its subsidiary UFO Interactive Group Limited ("UFO") has consolidated face-to-face and online education services and metaverse education services to provide hybrid learning experiences and upgrade its existing education services.
  • Bradaverse Education has been keeping pace with the times and actively deepening its education business.

Unitaid and the Global Health Innovative Technology Fund strengthen ties to improve access to critical health tools

Retrieved on: 
Tuesday, February 28, 2023

TOKYO and GENEVA, Feb. 28, 2023 /PRNewswire/ -- The Global Health Innovative Technology Fund (GHIT Fund) and global health agency Unitaid have signed a cooperation framework that aims to strengthen collaboration between the two agencies to increase cooperation between the Japanese research and development industry and the broader global health response.

Key Points: 
  • TOKYO and GENEVA, Feb. 28, 2023 /PRNewswire/ -- The Global Health Innovative Technology Fund (GHIT Fund) and global health agency Unitaid have signed a cooperation framework that aims to strengthen collaboration between the two agencies to increase cooperation between the Japanese research and development industry and the broader global health response.
  • This work will further efforts to ensure vulnerable and underserved populations have access to better health products and support progress towards universal health coverage.
  • "The recent COVID-19 pandemic has illustrated the importance of global collaboration in solving global problems," said Dr Philippe Duneton, Executive Director of Unitaid.
  • "Unitaid's reinforced partnership with the GHIT Fund will leverage ties with Japanese innovators who are addressing some of today's most pressing health challenges.

Footprint Announces Leadership Transitions and Promotes Corey Berends to Chief Operating Officer and Interim CEO

Retrieved on: 
Thursday, January 26, 2023

Footprint, a global materials science technology company focused on creating a healthy planet, today announces that Corey Berends has been promoted to Chief Operating Officer and Interim CEO.

Key Points: 
  • Footprint, a global materials science technology company focused on creating a healthy planet, today announces that Corey Berends has been promoted to Chief Operating Officer and Interim CEO.
  • As Chief Operating Officer, he will be responsible for Footprint’s day-to-day global operations, new product commercialization and sales.
  • Co-founder Troy Swope will continue to support the Company’s strategic sustainability engagement with key customers and support investor relationships while transitioning the leadership of the Company’s day-to-day operations to Corey Berends.
  • Troy will remain an integral member of our leadership team and a long-term contributor to the future successes of Footprint.

Bay Bridge Ventures Announces New Strategic Advisors in Climate Technology

Retrieved on: 
Tuesday, January 24, 2023

Bay Bridge Ventures (“Bay Bridge” or “the Firm”), an ESG and Sustainability focused venture capital firm investing in scalable, profitable, and impactful technology companies, today announced the appointment of three new strategic advisors focused on Climate Technology:

Key Points: 
  • Bay Bridge Ventures (“Bay Bridge” or “the Firm”), an ESG and Sustainability focused venture capital firm investing in scalable, profitable, and impactful technology companies, today announced the appointment of three new strategic advisors focused on Climate Technology:
    Tom Baruch, founder and Managing Director of Baruch Future Ventures, Partner Emeritus at Formation 8, and Advisor to Breakthrough Energy Ventures
    As a complement to Bay Bridge Ventures’ existing Advisors, Mr. Baruch, Mr. Roberts and Mr. Ramaswami each bring decades of industry and operating experience as well as a clear vision regarding the future of ESG and Climate Tech investing.
  • The firm’s previously announced Climate Technology Advisors include:
    “We are excited to have such an impressive group of advisors supporting the long-term success of Bay Bridge Ventures and providing access to expert technical advice for our portfolio companies,” said Kim Kolt, General Partner of Bay Bridge.
  • It’s the intentionality of thought leaders to commit capital into ‘entrepreneurial innovation’ that will purposefully transform the science and technology into meaningful contributions,” said Mr. Baruch.
  • Bay Bridge was founded by a world-class diverse team of General Partners, with more than 50 years of investment experience at organizations including CalPERS, Goldman Sachs, Credit Suisse in addition to well-known venture capital firms.

Advatix Announces Appointment of the USC Executive Director and Industry Expert Dr. Nick Vyas to its Advisory Board

Retrieved on: 
Thursday, February 2, 2023

WESTLAKE VILLAGE, Calif., Feb. 2, 2023 /PRNewswire/ -- Advatix, Inc., a leader in digital transformation of supply chains, announces the appointment of industry veteran, recognized thought leader, and authority on global supply chain management, Dr. Nick Vyas, to its Advisory Board. Dr. Vyas is the Founding Executive Director of the USC Marshall Randall R. Kendrick Global Supply Chain Institute that offers the world's leading master's program for Supply Chain.

Key Points: 
  • Advatix taps Dr. Nick Vyas, a global supply chain industry expert from USC Marshall Randall R. Kendrick Global Supply Chain Institute to provide industry guidance and support for the company's vision for global growth
    WESTLAKE VILLAGE, Calif., Feb. 2, 2023 /PRNewswire/ -- Advatix, Inc., a leader in digital transformation of supply chains, announces the appointment of industry veteran, recognized thought leader, and authority on global supply chain management, Dr. Nick Vyas, to its Advisory Board.
  • Dr. Vyas is the Founding Executive Director of the USC Marshall Randall R. Kendrick Global Supply Chain Institute that offers the world's leading master's program for Supply Chain.
  • Advatix Founder and CEO Manish Kapoor expressed, "We are thrilled to have Nick as our advisor.
  • He is a supply chain visionary who has led some of the world's leading businesses in their quests for growth.

The European Medicines Agency (EMA) Validated Regulatory Application for Arpraziquantel, a Potential Treatment for Schistosomiasis in Preschool-Aged Children

Retrieved on: 
Monday, January 23, 2023

Arpraziquantel, developed by the Pediatric Praziquantel Consortium, is a potential new treatment option tailored to improve child health by filling the treatment gap of an estimated 50 million preschool-aged children with schistosomiasis.

Key Points: 
  • Arpraziquantel, developed by the Pediatric Praziquantel Consortium, is a potential new treatment option tailored to improve child health by filling the treatment gap of an estimated 50 million preschool-aged children with schistosomiasis.
  • On behalf of the Pediatric Praziquantel Consortium, Merck submitted the regulatory application for arpraziquantel to the European Medicines Agency (EMA), which validated this application and started the scientific review process in December 2022.
  • Arpraziquantel represents the first investigational drug that has reached the regulatory phase amongst the portfolio of projects supported by GHIT Fund.
  • The drug praziquantel – the current standard treatment developed in the 1970s – is safe, effective and available for school-aged children and adults.

RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial

Retrieved on: 
Wednesday, January 18, 2023

RevBio, Inc., announced that it has received approval from the Italian Ministry of Health and the Ethics Committee of the University “G.D'Annunzio” of Chieti-Pescara to start a 15-patient pilot clinical trial.

Key Points: 
  • RevBio, Inc., announced that it has received approval from the Italian Ministry of Health and the Ethics Committee of the University “G.D'Annunzio” of Chieti-Pescara to start a 15-patient pilot clinical trial.
  • The primary objective of this study will be to assess the time it takes for Tetranite®, the company’s adhesive biomaterial, to regenerate bone in the mandibular and maxillary dental arches.
  • “The design of this study will answer some important questions that will help evidence the key advantages of this biomaterial,” said Dr. Fugazzotto.
  • “I believe this technology will be transformative in the way we place dental implants.”

T2 Biosystems Announces Extension of Multiyear Innovative Technology Contract with Vizient, Inc.

Retrieved on: 
Wednesday, December 28, 2022

LEXINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its Innovative Technology contract with Vizient, Inc., the largest member-driven health care performance improvement company in the country, has been extended through March 31, 2024.

Key Points: 
  • LEXINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its Innovative Technology contract with Vizient, Inc., the largest member-driven health care performance improvement company in the country, has been extended through March 31, 2024.
  • The products covered under the contract with Vizient include the T2Dx® Instrument, the T2Bacteria® Panel and the T2Candida® Panel, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood.
  • “We are pleased to extend our multi-year agreement with the nation’s largest group purchasing organization.
  • This reiterates the continued value that T2 Biosystems’ technology offers to patients suspected of sepsis,” stated John Sperzel, Chairman and CEO of T2 Biosystems.

IBN and BioMedWire Announce 3rd Year of Collaboration with Dynamic Global Events (DGE) to Serve as Official Media Partners for Upcoming 2023 Events

Retrieved on: 
Tuesday, December 13, 2022

BioMedWire (“BMW”), a specialized communications platform for the life sciences sector and one of the 50+ brands part of IBN , will also serve as an official media partner for DGE’s events throughout the next year.

Key Points: 
  • BioMedWire (“BMW”), a specialized communications platform for the life sciences sector and one of the 50+ brands part of IBN , will also serve as an official media partner for DGE’s events throughout the next year.
  • Major event categories include Diversity & Leadership, Medical Affairs, Clinical Affairs, Marketing & Communications, Patient Partnerships, and Innovative Technology.
  • For each of these events, IBN and BMW will offer dedicated virtual coverage, including syndicated articles with full dissemination to 5000+ strategic syndication partners such as Apple News.
  • “We are very pleased to be collaborating with IBN and BioMedWire again,” said Elizabeth Stanislaw, MBA, Marketing Manager of Dynamic Global Events.

Medical Grade Tubing Global Market Report 2022: Increasing Prevalence of Diseases to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 14, 2022

The global medical grade tubing market is projected to increase at an impressive rate through 2027.

Key Points: 
  • The global medical grade tubing market is projected to increase at an impressive rate through 2027.
  • Growing demand from medical purposes of medical tubing for fluid control and drainage, anesthesia and breathing apparatus, IVs, catheters, peristaltic pumps, and bio-pharmaceutical laboratories is influencing the market growth.
  • Apart from these, the rise in medical cases and diseases such as heart disease, cancer, lungs problem, and diabetes is projected to propel the growth of The medical grade tubing market.
  • In this report, global medical grade tubing market has been segmented into following categories, in addition to the industry trends which have also been detailed below: